Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ovarian cancer
Pharma
AZ faces FDA challenge as Imfinzi-Lynparza miss survival goal
At the final analysis of the Duo-O trial, Imfinzi and Lynparza failed to mount a survival benefit in first-line non-BRCA-mutated ovarian cancer.
Angus Liuu
Oct 19, 2025 4:15am
ESMO: Merck lays out Keytruda's landmark win in ovarian cancer
Oct 18, 2025 10:30am
In ovarian cancer, Keytruda follows PFS win with survival showing
Oct 16, 2025 10:23am
J&J will appeal $966M award by LA jury in talcum powder lawsuit
Oct 7, 2025 3:20pm
China approves 4 new drugs, including global 1st-in-class
Jul 2, 2025 11:32am
Keytruda delivers trial win in some patients with ovarian cancer
May 15, 2025 10:56am
